Abstract
Invasive lobular carcinoma (ILC) is the second most common subtype of breast cancer following invasive ductal carcinoma (IDC) and characterized by the loss of E-cadherin-mediated adherens junctions. Despite displaying unique histological and clinical features, ILC still remains a chronically understudied disease with limited knowledge on the available laboratory research models. To this end, herein we report a comprehensive 2D and 3D phenotypic characterization of four Estrogen Receptor-positive human ILC cell lines - MDA-MB-134, SUM44, MDA-MB-330 and BCK4. Compared to the IDC cell lines MCF7, T47D and MDA-MB-231, ultra-low attachment culture conditions revealed a remarkable anchorage-independence ability that was unique to the ILC cells, a feature not evident in soft agar gels. 3D Collagen I and Matrigel culture indicated a generally loose morphology for the ILC cell lines, which exhibited differing preferences for adhesion to ECM proteins in 2D. Furthermore, ILC cells had limited migration and invasion ability in wound-scratch and transwell assays with the exception of haptotaxis to Collagen I. Transcriptional comparison of the cell lines confirmed the decreased cell proliferation and E-cadherin-mediated intercellular junctions in ILC, while uncovering the induction of novel pathways related to cyclic nucleotide phosphodiesterase activity, ion channels, drug metabolism and alternative cell adhesion molecules such as N-cadherin, some of which were also differentially regulated in ILC versus IDC tumors. Altogether, these studies will serve as an invaluable resource for the breast cancer research community and facilitate further functional discoveries towards understanding ILC, identifying novel drug targets and ultimately improving the outcome of patients with ILC.
Authors’ Contributions Conception and design: N. Tasdemir, NE. Davidson, S. Oesterreich
Development of methodology: N. Tasdemir, L. Zhu, GC. Tseng, S. Oesterreich
Acquisition of data (performed experiments, processed data, etc.): N. Tasdemir, E. Bossart, Z. Li, Z. Li
Analysis and interpretation of data (e.g. biological interpretation, statistical analysis, computational analysis): N. Tasdemir, Z. Li, KM. Levine, NE. Davidson, S. Oesterreich
Writing, review and/or revision of the manuscript: N. Tasdemir, Z. Li, KM. Levine, BM. Jacobson, GC. Tseng, NE. Davidson, S. Oesterreich
Study supervision: NE. Davidson and S. Oesterreich
Footnotes
Financial Support: The work is in part funded by a Department of Defense Breakthrough Fellowship Award to NT (BC160764), Shear Family Foundation grant and Susan G. Komen Leadership grant to SO (SAC160073), Breast Cancer Research Foundation grants to NED and SO, and a grant (#4100070287) with Pennsylvania Department of Health. The Pennsylvania Department of Health specifically disclaims responsibility for any analyses, interpretations or conclusions. EB is supported by a National Institutes of Health (NIH) Ruth L. Kirschstein Award (1F31CA203055-01). ZL is supported by the University of Pittsburgh John S. Lazo Cancer Pharmacology Fellowship. KML is supported by an individual fellowship from the NIH/NCI (5F30CA203095) The project used the UPMC Hillman Cancer Center Biostatistics and Tissue and Research Pathology Services (TARPS) Cores, in part supported by P30CA047904.
Conflict of interest statement: None to report